Plasmapheresis and IVIG
Plasmapheresis
TREATMENT
Use of cellular and plasma apheresis in the critically ill patient, II: clinical indications and applications.
Linenberger ML, Price TH.
J Intensive Care Med. 2005;20:88-103.
Description : Review of the role of plasmapheresis in specific diseases and clinical indications for its use with a focus on the intensive care unit patient population.
PubMed citation number: 15855221
Applications of therapeutic apheresis in patients with malignant disease.
Pineda AA, Vamvakas EC.
Oncologist. 1997;2:94-103.
Description : This article presents guidelines and a brief review of study data regarding the use therapeutic apheresis in patients with malignancies including disease specific clinical indications, rational for treatment and management.
PubMed citation number: 10388036
Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis.
Smith JW, Weinstein R, for the AHCKL.
Transfusion. 2003;43:820-822.
Description : Evidence-based classification of the indications for therapeutic plasmapheresis as determined by the AABB and ASFA.
PubMed citation number: 12757535
Plasmapheresis in immune hematology: review of clinical outcome data with respect to evidence-based medicine and clinical experience.
von Baeyer H.
Ther Apher Dial. 2003;7:127-140.
Description : Review of clinical data and relevant literature to determine in an evidence-based medicine model, the efficacy of plasmapheresis in the management of immune-mediated disorders.
PubMed citation number: 12921129
IVIG
TREATMENT
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
George JN, Woolf SH, Raskob GE, et al.
Blood. 1996;88:3-40.
Description : Evidence-based recommendations and practice guidelines from an American Society of Hematology panel on the diagnosis and treatment of ITP, including the utilization of IVIg in this disorder.
PubMed citation number: 8704187
Intravenous immunoglobulin treatment in hematological diseases.
Otten A, Bossuyt PM, Vermeulen M, Brand A. Eur J Haematol. 1998;60:73-85.
Description : A literature review of the use of IVIg in hematologic diseases over a 16-year period to determine consistent treatment guidelines revealed no controlled clinical trials and limited documented evidence of the efficacy of IVIg as first-line treatment.
PubMed citation number: 9508347
Applications of intravenous immunoglobulin in haematology.
Todd AA, Yap PL.
Blood Rev. 1992;6:105-117.
Description : Specific utility of IVIg in both primary hematologic diseases as well as certain infectious and immune disorders as antibody replacement and/or immune modulator.
PubMed citation number: 1633507
Self-reported initial management of childhood idiopathic thrombocytopenic purpura: results of a survey of members of the American Society of Pediatric Hematology/Oncology, 2001.
Vesely SK, Buchanan GR, Adix L, et al.
J Pediatr Hematol Oncol. 2003;25:130-133.
Description : Review of physician-reported data on the management of pediatric ITP in an effort to design further randomized, controlled clinical trials to compare the different therapeutic modalities.
PubMed citation number: 12571464
Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center.
Zimmer J, Andres E, Noel E, Koumarianou A, Blickle JF, Maloisel F.
Clin Lab Haematol. 2004;26:137-142.
Description : Retrospective review of a patient cohort diagnosed with ITP to determine response rates to different therapeutic options, prognostic indicators, and final outcome. Data on the utilization of IVIg and patient response is included.
PubMed citation number: 15053808
Review
Blood component collection by apheresis.
Burgstaler EA.
J Clin Apheresis. Prepublished May 6, 2005.
Description : A technical article reviewing available equipment for plasmapheresis, which provides valuable information as to general principles of the technique.
PubMed citation number: 15880369
Use of cellular and plasma apheresis in the critically ill patient, I: technical and physiological considerations.
Linenberger ML, Price TH.
J Intensive Care Med. 2005;20:18-27.
Description : Discussion of the technical aspects (instruments, venous access) and physiologic considerations (hemodynamics, blood product exposure, anticoagulation) of plasmapheresis.
PubMed citation number: 15665256
Plasmapheresis: technique and complications.
Reimann PM, Mason PD.
Intensive Care Med. 1990;16:3-10.
Description : Discussion of the principles of plasmapheresis, technique, monitoring and complications.
PubMed citation number: 2179349